Search Results
Your search for this matches 25378 pages
Showing 23801 - 23850NRAS Mutations in Advanced Melanoma Correlate With Increased Benefit From Immunotherapies
Researchers investigating whether tumor genotype correlates with benefit from immune therapy in melanoma has found that patients whose tumors had NRAS mutations had better response to immunotherapy and better outcomes than patients whose tumors had other genetic subtypes. The results suggest that...
Study Finds Immunohistochemistry Is More Effective Than FISH in Detecting EML4-ALK Rearrangments in Lung Cancer
A retrospective study by Pekar-Zlotin et al investigating fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) for detecting EML4-ALK rearrangement in patients with lung cancer has found that FISH may miss a significant number of patients who tested positive with...
Sipuleucel-T Demonstrates Sustained Immune Response 2 Years After Treatment in Biochemically Recurrent Prostate Cancer
Preliminary results from the phase II STAND trial have demonstrated a robust immune response with sipuleucel-T (Provenge) that continues 2 years after completing treatment in men with biochemically recurrent prostate cancer. The findings, along with data from an ongoing phase IV registry related to ...
Study Shows Lack of RNA Editing Leads to Melanoma Growth and Metastasis
In a new study reported by Shoshan et al in Nature Cell Biology, researchers at The University of Texas MD Anderson Cancer Center established a link between melanoma and lack of RNA editing, which leads to tumor growth and progression through manipulation of proteins. Study Findings Study lead...
Novel Cell Profiling Technique May Help Personalize Cancer Treatments
Researchers have developed a lab test called Dynamic BH3 Profiling (DBP) to measure early changes in net proapoptotic signaling at the mitochondrion induced by chemotherapeutic agents in cancer cells. In cell-line and clinical experiments, the test accurately predicted chemotherapy response across...
Active Surveillance of Intermediate-Risk Prostate Cancer Associated With Decreased Survival
An analysis of data on 945 patients with prostate cancer that is managed with active surveillance shows differences in outcomes depending on whether the patient was low or intermediate risk at diagnosis. Compared to patients with low-risk disease, those with intermediate-risk cancer (PSA > 10...
Adjuvant Sorafenib and Sunitinib Do Not Improve Outcomes in Locally Advanced Kidney Cancer
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant sorafenib (Nexavar) or sunitinib (Sutent). The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery ...
Men Who Have Had Testicular Cancer May Be More Likely to Develop Prostate Cancer
A case-control study of close to 180,000 men suggests that the incidence of prostate cancer is higher among men with a history of testicular cancer (12.6%) than among those without a history of testicular cancer (2.8%). Men who have had testicular cancer were also more likely to develop...
Early Evidence of Increase in Higher-Risk Prostate Cancers From 2011 to 2013
An analysis of data on roughly 87,500 men treated for prostate cancer since 2005 found a notable increase in higher-risk cases of the disease between 2011 and 2013. The retrospective analysis of patient data found the proportion of men diagnosed with intermediate- and high-risk disease increased by ...
Androgen Receptor Abnormality May Not Be Associated With Primary Resistance to Taxane Chemotherapy
Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer. Treatment outcomes were largely similar for the 17 patients with...
New Model Provides Improved Prediction of Breast Cancer Risk in African American Women
Breast cancer risk prediction models have underestimated the risk for African American women, a factor that has contributed to lower rates of recruitment to prevention trials in this population. In a study reported in the Journal of Clinical Oncology, Boggs et al developed a risk model, derived...
Final 8-Year Analysis of Intergroup Trial Shows Survival Benefit With Addition of Radiotherapy to Androgen-Deprivation Therapy in Prostate Cancer
In the final prespecified analysis of an Intergroup trial (NCIC Clinical Trials Group PR.3/Medical Research Council PR07/Intergroup T94-0110) reported in the Journal of Clinical Oncology, Mason et al found that overall survival and cancer-specific survival at 8 years were significantly greater with ...
Improved Prognosis for Patients With Estrogen Receptor–Positive Breast Cancer With Large Reductions in Mammographic Density After Tamoxifen Initiation
Improved prognosis for women with estrogen receptor–positive breast cancer who experience a large reduction in mammographic density following the initiation of tamoxifen treatment extends to premenopausal as well as postmenopausal women, researchers reported in the Journal of the National...
Emergency Room Visits and Hospitalizations Are Common Among Women With Early Breast Cancer Receiving Chemotherapy
Emergency room visits and hospitalizations are common among patients with early breast cancer receiving chemotherapy, particularly among those receiving a regimen containing docetaxel, according to a report by Enright et al in the Journal of Oncology Practice. “In this population-based cohort ...
No Progression-Free Survival Benefit of Adding Bevacizumab to Endocrine Therapy in First-Line Treatment for Advanced Breast Cancer
In a Spanish-German phase III LEA trial reported in the Journal of Clinical Oncology, Martín et al found that adding bevacizumab (Avastin) to endocrine therapy with letrozole or fulvestrant (Faslodex) in the first-line treatment of postmenopausal women with advanced breast cancer did not...
Sensor Technology May Help Improve the Accuracy of Clinical Breast Exams
Sensor technology has the potential to significantly improve the teaching of proper technique for clinical breast exams, according to a new study by researchers at the University of Wisconsin School of Medicine and Public Health. The results of the study were published in a correspondence in The...
FDA Approves Lenalidomide in Combination With Dexamethasone for Newly Diagnosed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has expanded the existing indication for lenalidomide (Revlimid) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma. Lenalidomide plus dexamethasone was previously approved in June 2006 for use in multiple myeloma...
Reduction in Late Toxicities With Preoperative Image-Guided Radiation Therapy to Reduced Target Volume in Patients With Extremity Sarcoma
As reported in the Journal of Clinical Oncology by Wang et al, the incidence of late toxicity among patients with extremity soft-tissue sarcoma receiving preoperative image-guided radiotherapy to a reduced target volume in the phase II Radiation Therapy Oncology Group (RTOG) 0630 trial was lower...
Survivors of Childhood Cancer at Risk for Developing Hormone Deficiencies as Adults
Decades after undergoing cranial irradiation for childhood cancer, St. Jude Children's Research Hospital investigators found that adult survivors of pediatric cancer remain at risk for pituitary hormone deficiencies, which may diminish their health and quality of life. Chemaitilly et al published...
12-Year Study Suggests Procedures to Prevent Cervical Cancer Do Not Affect Fertility
Common surgical procedures used to diagnose and treat precancerous cervical lesions do not decrease women's chances of becoming pregnant, according to a study conducted by Kaiser Permanente Northwest, which followed nearly 100,000 women for up to 12 years. In fact, researchers found that women ...
Early Study Suggests Olaparib May Be Effective in Ovarian Cancers Expressing High Levels of POLQ
Last December, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) in the treatment of advanced ovarian cancer in women with BRCA1 or BRCA2 gene mutations. Now, a laboratory study by Ceccaldi et al has found that the drug may also be effective in breast and ovarian tumors that...
Urea-Based Cream Prevents Sorafenib-Associated Hand-Foot Skin Reactions in Chinese Patients With Advanced Hepatocellular Carcinoma
In a Chinese study reported in the Journal of Clinical Oncology, Ren et al found that prophylactic use of urea-based cream reduced the incidence of sorafenib (Nexavar)–associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. Urea-based creams are used to treat...
‘Frailty Profile’ Predicts Survival and Toxicities Among Elderly Patients With Multiple Myeloma
A frailty score predicts mortality and the risk of toxicity in elderly patients with multiple myeloma and can be used to determine more suitable therapies for these patients, the International Myeloma Working Group reported in Blood. “Chronologic age, performance status, and physician's...
ASCO Expresses Concern Over the New CMS Oncology Care Model
On Thursday, February 12, 2015, the U.S. Department of Health and Human Services announced its new Oncology Care Model, a multipayer payment and care delivery model meant to support better health-care coordination for patients with cancer. Although commending the Centers for Medicare & Medicaid ...
Durable Remissions With Brentuximab Vedotin in Patients With CD30-Positive Relapsed/Refractory Diffuse Large B-Cell Lymphoma
A phase II, open-label study evaluating the efficacy of brentuximab vedotin (Adcetris), an anti-CD30 antibody-drug conjugate, found that among 48 evaluable patients with CD30-positive diffuse large B-cell lymphoma, 21 (44%) had objective responses. This total included 8 patients (17%) with complete ...
Nutrient-Wide Association Study Shows Increased Coffee Intake May Be Associated With Lower Risk of Endometrial Cancer
Women who drank about four cups of coffee per day appeared to have decreased endometrial cancer risk compared with those who drank less than a cup each day, according to a study published by Merritt et al in Cancer Epidemiology, Biomarkers & Prevention. A New Approach “We used a...
Lenvatinib Shows Promise for Patients With Radioiodine-Refractory Thyroid Cancer in Phase III Study
In a phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral antiangiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer. Their findings are published by...
Japanese Phase III Trial Shows No Survival Benefit of First-Line Weekly Cisplatin/Docetaxel vs Docetaxel in Elderly Patients With Advanced NSCLC
In a Japanese phase III trial (Intergroup Trial JCOG0803/WJOG4307L) reported in the Journal of Clinical Oncology, Abe et al found no overall survival benefit of weekly cisplatin/docetaxel vs standard docetaxel in the first-line treatment of elderly patients with advanced non–small cell lung...
Meaning-Centered Group Psychotherapy Improves Psychological Well-Being in Patients With Advanced Cancer
In a randomized trial reported in the Journal of Clinical Oncology, Breitbart et al found that meaning-centered group psychotherapy significantly improved psychological well-being compared with supportive group psychotherapy in patients with advanced or terminal cancer. Meaning-centered group...
Scientists Identify Genetic Variations Linked to Treatment-Related Hearing Loss in Young Patients With Cancer
Using a genome-wide associated study approach, researchers have identified inherited genetic variations in the ACYP2 gene that were linked to as much as a fourfold greater risk of rapid hearing loss in young patients with newly diagnosed brain tumors treated with cisplatin chemotherapy. The study...
Adding Sorafenib to Standard Therapy of No Benefit in Advanced Ovarian Cancer, Study Reveals
In a study of women with stage III/IV epithelial ovarian cancer, the addition of sorafenib (Nexavar) to traditional paclitaxel/carboplatin therapy resulted in no greater efficacy and increased toxicity, according to a report by Hainsworth et al in Cancer Medicine. The investigators suggested that...
Active Smoking Increases Mortality in Nonmetastatic Colorectal Cancer, Both Pre- and Postdiagnosis
In a study reported in the Journal of Clinical Oncology, Yang et al found that current smoking was associated with increased colorectal cancer–specific and all-cause mortality among colorectal cancer patients in both the prediagnosis and postdiagnosis settings. Study Details The study...
Higher Than Expected Incidence of Marrow Neoplasms after Adjuvant Therapy for Breast Cancer
In a study reported in the Journal of Clinical Oncology, Wolff et al found a low but higher-than-expected incidence of marrow neoplasms in patients receiving adjuvant radiation therapy or chemotherapy for breast cancer. The study used the National Comprehensive Cancer Network Breast Cancer...
Study Identifies Eight Signs Associated With Impending Death in Cancer Patients
Researchers at The University of Texas MD Anderson Cancer Center have identified eight highly specific physical and cognitive signs associated with imminent death in cancer patients. The findings, published by Hui et al in Cancer, could offer clinicians the ability to better communicate with...
Phase III Study Shows Significant Benefit of Obinutuzumab in Refractory Indolent Non-Hodgkin Lymphoma
In a preplanned interim analysis of the phase III GADOLIN trial, obinutuzumab (Gazyva) plus bendamustine (Trenada) followed by obinutuzumab alone was found to significantly improve progression-free survival compared to bendamustine alone in patients with indolent, refractory non-Hodgkin lymphoma....
Reduced Use of Radiotherapy for Unresectable Pancreatic Adenocarcinoma in the United States
In a study reported in a research letter in JAMA Surgery, Shapiro et al found that use of radiotherapy in unresectable pancreas cancer has decreased over time and that disparities in use can be identified. Decreasing Use The study involved Surveillance, Epidemiology, and End Results (SEER) data...
Widespread Use of Docetaxel Preceded Phase III Evidence of Usefulness in Patients With Metastatic Prostate Cancer
Docetaxel was being widely used by patients with metastatic prostate cancer before phase III evidence that it was more effective than standard-of-care for patients with castration-resistant prostate cancer, according to an analysis of Medicare claims from before and after the trial results and...
Women Who Undergo Delayed Breast Reconstruction May Experience More Cancer‑Related Distress Than Women Who Undergo Mastectomy Alone
In women who have undergone mastectomy, those who underwent delayed breast reconstruction experienced greater cancer-related distress over the long term compared with women who underwent mastectomy alone, according to a prospective study by Metcalfe et al in the Journal of Surgical Oncology. For...
Study Shows Immunosuppressives, Chemotherapy May Reactivate Hepatitis B
Individuals previously infected with the hepatitis B virus (HBV) that receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the virus, according to a report published by Di Bisceglie et al in Hepatology. Reactivation of HBV can be fatal, and researchers suggest routine...
Genetic Screening Deemed Cost-Effective in
Non–Small Cell Lung Cancer
Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements, and subsequent biomarker-guided treatment, is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic...
CMS Issues National Coverage Determination for Screening for Lung Cancer With Low-Dose Computed Tomography
Today the Centers for Medicare & Medicaid Services (CMS) issued a final national coverage determination that provides for Medicare coverage of screening for lung cancer with low-dose computed tomography (CT). The coverage is effective immediately. “This is the first time that Medicare...
Patients With Detectable PSA After Radical Prostatectomy May Benefit From More Aggressive Radiotherapy, 10-Year Post-Treatment Analysis Shows
Prostate cancer patients with detectable prostate-specific antigen (PSA) following radical prostatectomy should receive earlier, more aggressive radiotherapy, according to a study published by Wiegel et al in the International Journal of Radiation Oncology • Biology • Physics. German ARO ...
Analysis of Key Breast Cancer Genes Reveals Distinct Profiles for African American, European American Women
Researchers at Roswell Park Cancer Institute (RPCI) have uncovered new information that may begin to explain why many African American women are more likely to be diagnosed with aggressive, often deadly forms of breast cancer. Their findings also strengthen evidence that increased dietary folate...
Phase II Study Shows Activity of Everolimus and Letrozole in Recurrent Endometrial Carcinoma
Interaction of the estrogen receptor and PI3K/AKT/mTOR pathways and the finding of resistance to hormonal therapy mediated by PI3K activation suggest a benefit of adding an mTOR inhibitor to hormonal treatment in endometrial carcinoma. In a phase II study reported in the Journal of Clinical...
Immune Gene Profile Strongly Associated With Benefit of Adjuvant Trastuzumab in HER2-Positive Breast Cancer
In a study reported in the Journal of Clinical Oncology, Perez et al found that an immune function gene profile was associated with significantly improved relapse-free survival among patients with early-stage HER2-positive breast cancer who had trastuzumab (Herceptin) added to adjuvant chemotherapy ...
Evidence of Recurrence-Free, Disease-Free, and Overall Survival Benefit of Aspirin and COX-2 Inhibitors in Stage III Colon Cancer
In a study reported in the Journal of the National Cancer Institute, Ng et al found consistent trends suggesting benefit of aspirin use and COX-2 inhibitor use on recurrence-free, disease-free, and overall survival in patients with stage III colon cancer. Study Details This prospective...
FDA Approves Palbociclib in Combination With Letrozole for Advanced Breast Cancer
The U.S. Food and Drug Administration has granted accelerated approval to palbociclib (Ibrance) in combination with letrozole for the treatment of postmenopausal women with estrogen receptor–positive, HER2-negative metastatic breast cancer who have not yet received an endocrine-based therapy. ...
Study Sheds New Light on Syndrome Associated With Aggressive Pediatric Cancer
A new study involving researchers at The University of Nottingham has revealed how children with an aggressive cancer predisposition syndrome experience a never-before- seen flood of mutations in their disease in very short periods of time. The findings were published by Shlien et al in Nature...
Dabrafenib May Stimulate Radioiodine Uptake in Patients With Iodine-Refractory Papillary Thyroid Cancer
In patients with iodine-refractory papillary thyroid cancer, the addition of dabrafenib (Tafinlar) therapy was shown to stimulate radioiodine uptake in thyroid cancer cells, according to a report by Rothenberg et al in Clinical Cancer Research. This approach has the potential advantage of requiring ...
Crizotinib Produces Systemic and Intracranial Disease Control in Patients With Advanced ALK-Rearranged NSCLC and Brain Metastases
In a retrospective analysis reported in the Journal of Clinical Oncology, Costa et al found that crizotinib (Xalkori) treatment resulted in high systemic and intracranial disease control rates in patients with ALK-rearranged non–small cell lung cancer (NSCLC) who had asymptomatic brain...
